Results of Numerous Trials in Multiple Myeloma (MM) With Thalomid, Revlimid, and Velcade Proved Overwhelmingly Positive - ASCO Review Part II Featuring Key Studies on the Oncology Area.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c42727) has announced the addition of Financial Markets Research: ASCO ASCO American Society of Clinical Oncology ASCO Association of Schools and Colleges of Optometry (since 1941; Rockville, Maryland) ASCO Australian Standard Classification of Occupations ASCO Automatic Switch Company Review Part II - A Summary of Highlights Presented at the ASCO 2006 Annual Meeting to their offering ASCO features key presentations in the oncology area, and is generally the most important week of the year for oncology. Presented are comments on the most important events at the 2006 conference. Scope of this title: * A summary of highlights presented at ASCO 2006 on Monday June 4, 2006, as well as information on related presentations from earlier in the conference * Drugs covered include Celgenes Thalomid (thalidomide thalidomide (thəlĭd`əmĭd'), sleep-inducing drug found to produce skeletal defects in developing fetuses. The drug was marketed in Europe, especially in West Germany and Britain, from 1957 to 1961, and was thought to be so safe that ) & Revlimid (lenalidomide), Genentechs Avastin (bevacizumab), Millenniums Velcade (bortezomib) Highlights of this title: * Continuing a disappointing weekend, Nexavar was unable to show a statistically significant survival benefit in second-line metastatic Metastatic The term used to describe a secondary cancer, or one that has spread from one area of the body to another. Mentioned in: Coagulation Disorders metastatic pertaining to or of the nature of a metastasis. renal cell carcinoma renal cell carcinoma or hypernephroma Malignant tumour of the cells that cover and line the kidney. It usually affects persons over age 50 who have vascular disorders of the kidneys. It seldom causes pain, unless it is advanced. (RCC RCC - An extensible language. ) in an update from the trial that led to its FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval. But, we believe that reports that Nexavar has failed to show a survival benefit appear to be misleading. * The author notes that while data presented at ASCO has given Sutent frontrunner status in first-line therapy in RCC, results from trials examining various targeted agents have suggested that these therapies may be used sequentially in metastatic disease. * Results of numerous trials in multiple myeloma multiple myeloma A malignant proliferation of abnormal plasma cells that populate the marrow-containing bones of the body. The affected plasma cells produce myeloma protein, a monoclonal antibody that replaces normal antibodies in the blood, thereby increasing susceptibility (MM) with Thalomid, Revlimid, and Velcade proved overwhelmingly positive, with high efficacy and superiority over standard regimens in both front-line and later-line settings. The optimal regimen is being evaluated in ongoing clinical trials, from which we expect data to emerge over the next two years. Reasons to read this report: * Identify the most important events that occurred at ASCO 2006 * Understand the impact of key data presentations on the potential future dynamics of the oncology market The Contents inside this report include: Summary GSKs lapatinib and BMYs dasatinib are the early stars ASCO Coverage Key highlights Tykerb (Lapatinib) Highlights GSKs lapatinib living up to hype in breast cancer FDA approval likely, but more Phase III success needed to maximize market Lapatinib disappoints in renal cell carcinoma Subset analysis provides hope, but with reduced patient potential Highlights In Chronic Myeloid Leukemia Following recommendation for FDA approval, presented data confirms Sprycel (dasatinib) efficacy in chronic myeloid leukemia Dasatinib possibly more effective than high dose Gleevec Will dasatinib eventually become first-line therapy? Dasatinib maintains its lead on potential competitor, Novartiss AMN Amn abbr. airman 107 Highlights In Renal Cell Carcinoma Sorafenib vs. Sutent battle continues in the abstract Lack of sorafenib front-line data paves way for Sutent success Wyeth drug may find niche in poor-risk patients after demonstrating survival benefit Smaller studies underscore advances in renal cell carcinoma Erbitux (Cetuximab) Highlights Strong Erbitux data suggests expanding role as companies brace for competition Front-line data interesting, but lack of Avastin leaves physicians looking forward to 2007 Erbitux ready to advance in NSCLC NSCLC non (or cancer). NSCLC Non-small cell lung cancer, see there Highlights In Non-Small Cell Lung Cancer Lung Cancer, Non-Small Cell Definition Non-small cell lung cancer (NSCLC) is a disease in which the cells of the lung tissues grow uncontrollably and form tumors. Description There are two kinds of lung cancers, primary and secondary. Frontrunner yet to emerge in next wave of targeted NSCLC therapies success will likely require combination therapy Zactima Sutent Nexavar Summary Denosumab Highlights Phase II data positive for denosumab but phase III trial needed Denosumab appears at least equal to Novartiss Zometa in the treatment of bone metastases Too early to tell whether denosumab will cause osteonecrosis osteonecrosis /os·teo·ne·cro·sis/ (os?te-o-ne-kro´sis) necrosis of a bone. os·te·o·ne·cro·sis n. Necrosis of bone. , but no cases have occurred yet Denosumab could become mainstay of bone metastases treatment but filing likely a long way off Appendix Our Healthcare Disclosure information Ask the analyst For more information visit http://www.researchandmarkets.com/reports/c42727 Source: Datamonitor |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion